

Theranostic nanocages for imaging and photothermal therapy of prostate cancer cells by active targeting of neuropeptide-Y receptor


Svetlana Avvakumova, Elisabetta Galbiati, Laura Sironi, Silvia A. Locarno, Luca Gambini, Chiara Macchi, Laura Pandolfi, Massimiliano Ruscica, Paolo Magni, Maddalena Collini, Miriam Colombo, Fabio Corsi, Giuseppe Chirico, Sergio Romeo, and Davide Proserpi

Bioconjugate Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.bioconjchem.6b00568 • Publication Date (Web): 03 Nov 2016

Downloaded from <http://pubs.acs.org> on November 5, 2016

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.



TOC graphic

85x42mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Theranostic Nanocages for Imaging and Photothermal Therapy of Prostate Cancer Cells by Active Targeting of Neuropeptide-Y Receptor

*Svetlana Avvakumova,¹ Elisabetta Galbiati,¹ Laura Sironi,² Silvia A. Locarno,³ Luca Gambini,³
Chiara Macchi,⁴ Laura Pandolfi,¹ Massimiliano Ruscica,⁴ Paolo Magni,⁴ Maddalena Collini,²
Miriam Colombo,¹ Fabio Corsi,⁵ Giuseppe Chirico,² Sergio Romeo,³ and Davide Prosperi^{1,*}*

¹ NanoBioLab, Dipartimento di Biotecnologie e Bioscienze e Centro di Nanomedicina, Università di Milano-Bicocca, Piazza della Scienza, 2, 20126, Milano, Italy. ² Dipartimento di Fisica e Centro di Nanomedicina, Università di Milano-Bicocca, Piazza della Scienza 3, 20126, Milano, Italy. ³ Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche, via Mangiagalli 25, 20133 Milano, Italy. ⁴ Università degli Studi di Milano, Dipartimento di Scienze Farmacologiche e Biomolecolari, via Balzaretti 9, 20133 Milano, Italy. ⁵ Surgery Department, Breast Unit, ICS Maugeri S.p.A. SB, via S. Maugeri 10, 27100 Pavia, Italy.

Email: davide.prosperi@unimib.it

KEYWORDS: Neuropeptide Y; gold nanocages; theranostics; molecular imaging; photothermal treatment; prostate cancer

1
2
3
4
5
6
7 ABSTRACT: Gold nanocages (AuNCs) have been shown to be a useful tool for harnessing
8
9
10 imaging and hyperthermia therapy of cancer, thanks to their unique optical properties, low
11
12 toxicity and facile surface functionalization. Herein, we use AuNCs for selective targeting of
13
14 prostate cancer cells (PC3) via specific interaction between neuropeptide Y (NPY) receptor and
15
16 three different NPY analogs conjugated to AuNCs. Localized surface plasmon band of the
17
18 nanoconjugates was set around 800 nm, which is appropriate for in vivo applications. Long-term
19
20 stability of nanoconjugates in different media was confirmed by UV-vis and DLS studies. Active
21
22 NPY receptor targeting was observed by confocal microscopy showing time-dependent AuNCs
23
24 cellular uptake. Activation of ERK1/2 pathway was evaluated by Western blot to confirm the
25
26 receptor-mediated specific interaction with PC3. Cellular uptake kinetics were compared as a
27
28 function of peptide structure. Cytotoxicity of nanoconjugates was evaluated by MTS and
29
30 Annexin V assays, confirming their safety within the concentration range explored.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Hyperthermia studies were carried out irradiating the cells, previously incubated with AuNCs, with a pulsed laser at 800 nm wavelength, showing a heating enhancement ranging from 6 to 35 °C above the culture temperature dependent on the irradiation power (between 1.6 and 12.7 W/cm²). Only cells treated with AuNCs underwent morphological alterations in the cytoskeleton structure upon laser irradiation, leading to membrane blebbing and loss of microvilli associated to cell migration. This effect is promising in view of possible inhibition of proliferation and invasion of cancer cells. In summary, our Au-peptide NCs proved to be an efficient theranostic nanosystem for targeted detection and activatable killing of prostate cancer cells.


INTRODUCTION

A great challenge in modern oncology resides in the detection, localization and treatment of tumor neoplasms, especially at early stages of development. Among different conventional strategies used to selectively target cancer cells, monoclonal antibodies have become a magic bullet.^{1,2} However, numerous drawbacks in antibody treatments have appeared with time, including poor pharmacokinetics and biodistribution as well as compromised functionality of the immune system,³ making this solution more complicated than expected.⁴ As an alternative to the use of antibodies, synthetic peptides reminiscent of those naturally occurring in the human organism, so called regulatory peptides, are gaining increasing interest in cancer research.⁵ Short peptides can be easily synthesized using automated synthesizers and their pharmacokinetic profiles can be improved by making appropriate changes in the peptide sequence. Regulatory peptides include brain neuropeptides, gut peptide hormones, vasoactive peptides, and peptides of the endocrine system, and act on multiple targets in the human body modulating the function of most key organs and metabolic processes.⁶ More recently, these regulatory peptides have been suggested as powerful small ligands for cancer targeting, as several peptide receptors were found overexpressed in certain tumors, and indicated for use as markers for localization of tumors and of their metastases.⁷ Actually, advanced clinical diagnosis of cancer takes advantage of molecular receptor targeting by radiolabeled peptides.^{3,8} The major challenge for radiolabeling is to find a compromise between peptide and radionuclide dosages: a minimum amount of peptide is needed to reduce any adverse pharmacologic effects, while high specific radioactivity is crucial for optimal resolution. On the other hand, the potential of nuclear imaging techniques (PET, SPECT) is limited by the cost of radionuclides with short half-lives and relatively poor

1
2
3 resolution. In the last decade, great efforts have been made to develop new kinds of imaging
4 agents taking advantage of the progress made by nanoparticle research.⁹ Among myriads of
5 nanoparticles, gold nanocages (AuNCs), versatile nanostructures characterized by hollow
6 interiors and ultrathin porous walls, have attracted a great attention thanks to their unique optical
7 properties associated to a tunable localized surface plasmon resonance (LSPR).¹⁰ The two- and
8 three-photon luminescence capabilities and strong optical absorption of AuNCs allow labeling
9 and quantitatively tracking the cells using two-photon and photoacoustic microscopy, therefore
10 providing valid alternative to radiolabeling.^{11,12,13} In addition, AuNCs have been used as
11 promising agents for noninvasive photothermal therapy taking advantage of the large absorption
12 cross-section in the near infrared (NIR) region of the optical spectrum.^{14,15} More recently gold
13 nanoparticles have been shown to display substantial Joule heating under radiofrequency fields,
14 opening up their application in MRI therapy,^{16,17} though the mechanisms and efficiency of this
15 effect is still under debate. Finally, the easy functionalization of AuNCs with thiol-containing
16 molecules through Au-S covalent interaction make them excellent nanoconjugates for use as
17 tumor targeting agents. Combined together, these features give rise to an efficient
18 multifunctional nanotheranostics able to label and detect tumor cells via specific targeting of
19 molecular receptors and to induce their irreversible death through NIR-assisted
20 hyperthermia.^{18,19,20}

21
22 Despite the remarkable progress in the field of small peptides as targeting agents, the
23 exploration of new peptide receptors overexpressed preferentially by human cancers remains an
24 attractive goal in order to optimize the therapeutic possibilities toward a personalized cure. In
25 this context, neuropeptides play a crucial role being not only potent cellular growth factors in
26 normal cells, but also responsible for autocrine/paracrine stimulation of tumor cell proliferation

1
2
3 and migration.⁵ Neuropeptide Y (NPY) is a 36 amino acid peptide that acts as a neurotransmitter
4 and neuromodulator and, in humans, exerts its effect through a family of four G-protein coupled
5 receptors, namely, Y1, Y2, Y4, and Y5. In particular, the expression of Y1, Y2, and Y5 receptors
6 is associated with different stages of either carcinogenesis or tumor progression.⁵ Recent studies
7 by Magni *et al.* explored the expression of Y1-R gene in prostate cancer cells and the role of
8 NPY in regulating tumor growth.²¹ However, the attention has been mostly focused on GPCR
9 itself so far, while the data regarding NPY receptor (NPYR) targeting in prostate cancer are still
10 lacking. Aiming to explore the potential of NPYR targeting in the treatment of prostate cancer,
11 we prepared gold nanocages functionalized with three short peptides – derivatives of NPY –
12 specific to NPYR (Y1/Y2). These Au-peptide nanocages were first assessed in terms of targeting
13 efficiency in PC3 prostate cancer cells. Next, the nanoconjugates were exploited as probes for
14 confocal microscopy and as heating mediators for light-triggered cancer thermotherapy, taking
15 advantage of the theranostic character of AuNCs (Figure 1).
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1
2
3 **Figure 1.** Schematic representation of NPYR targeting on prostate cancer cells by peptide-
4 functionalized gold nanocages and subsequent hyperthermia by NIR irradiation. Three kinds of
5 AuNCs are considered, deriving from the surface functionalization with selected peptides,
6 namely a) Au-CALNN-INP, b) Au-CALNN-Ahx-INP, c) Au-CALNN-YIN, respectively.
7 Peptide sequences are sketched in the figure. The available surface of AuNCs was saturated by
8 short PEG molecules, HS-(CH₂)₁₁-EG6-OH.
9
10
11
12
13
14
15
16
17
18
19

20 RESULTS AND DISCUSSION

21 **Design and synthesis of peptides.** The rationale of peptide design was based on the following
22 issues: 1) preservation of the native alpha-helical conformation of NPY, essential for the NPYR
23 recognition, and 2) successful conjugation of the peptides to AuNCs giving stable nanoparticles
24 without compromising the receptor recognition ability. Peptide structures, reported in Figure 1,
25 contain a nanoparticle-binding motif (CALNN) and a NPY-binding motif. NPY-binding motifs
26 were synthesized according to the results of the studies reported previously.²² CALNN
27 pentapeptide, successfully used by Levy *et al.* to favor an ordered peptide assembly on the
28 nanoparticle surface, was introduced as a linker for AuNCs stabilization via Au-thiol bond of
29 terminal Cys.²³ As for NPYR binding part, the binding motifs were derived from the C-terminus
30 NPY 25-36 fragment - common recognition site for the receptor binding conserved in all of the
31 ligands.²⁴ In brief, the amidated C-terminus as well as the Arg33 and Arg35 residues were
32 conserved for their importance in maintaining the NPYR binding. As for CALNN-INP, Leu30
33 was exchanged with Pro in order to increase the fragment activity since the turn-inducing
34 sequence Asn29-Pro30 stabilizes the essential helix conformation. To improve the segment
35 helicity, Gln34 was also substituted with Leu in all three peptides, while Thr32 was exchanged
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 with aromatic amino acids like Phe or Tyr to increase the peptide-receptor interaction.²⁵ In
4
5 CALNN-Ahx-INP, 6-aminohexanoic acid (Ahx) was introduced between the nanoparticle-
6
7 binding motif and the NPY-binding motif for two reasons: 1) to study how the sequence CALNN
8
9 could influence the stability of the peptide secondary structure when it is directly or not linked to
10
11 the receptor-binding motif; 2) to study possible effects of an elongation and separation of the
12
13 receptor-binding motif from nanoparticle surface on the targeting efficiency of the
14
15 nanoconjugate. Peptides were synthesized manually by Fmoc-strategy using the Rink Amide
16
17 resin, purified by a preparative HPLC and characterized by analytical HPLC. The identity and
18
19 purity were confirmed by UPLC mass spectrometry. The peptide secondary structure was studied
20
21 by circular dichroism (CD). The CD spectra, shown in the Figure S1, were performed in
22
23 phosphate buffer saline (PBS)/TFE 70:30 (10 μ M solutions) in the far-UV region (190-250 nm).
24
25 As expected, in the case of CALNN-INP and CALNN-YIN, the double minima at 208 and 222
26
27 nm and the positive band below 200 nm indicate the presence of a well-defined helical structure.
28
29 The percentage of α -helix in the peptides was calculated with DICHROWEB²⁶ using K2d
30
31 method,²⁷ which estimated a value of 56% and 55% respectively. Then, the presence of Pro in
32
33 position 30 allowed to maintain the helical secondary structure also with a shorter sequence. In
34
35 CALNN-Ahx-INP, the typical bands of α -helix structure disappeared (only 28% calculated with
36
37 DICHROWEB), but it exhibited a negative band at 218 nm and a positive band at 193 nm,
38
39 typical of an antiparallel β -pleated sheets. These results suggested that the pentapeptide CALNN
40
41 could be considered useful not only for the assembly on the nanoparticle surface, but also for the
42
43 stabilization of the helical structure when it is directly linked to the peptide receptor-binding
44
45 motif.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Nanoparticle synthesis and functionalization.** PVP-coated AuNCs of 40.8 ± 1.8 nm were
4 prepared by well-described galvanic replacement using silver nanocubes as substrates (Figure 2,
5 a-c).^{28,29} To prepare the three different batches of functionalized AuNCs, as-synthesized
6 nanoparticles were reacted with a mixture of each peptide type and thiolated PEG to allow for
7 capping-ligand exchange and Au-S bond formation. As above mentioned, the CALNN sequence
8 was used as a spacer between AuNC surface and the targeting moiety. CALNN peptide allowed
9 keeping the colloidal stability of nanoconjugates by stabilization of the targeting peptide
10 structure and its interaction with the charged nanoparticle surface.²³ As discovered by Levy *et*
11 *al.*, thanks to the presence of alanine and leucine in positions 2 and 3 promoting the self-
12 assembly of the peptide through intermolecular hydrophobic interactions, CALNN peptide is
13 able to form a self-assembled monolayer on gold nanoparticles, donating to nanoparticles
14 extremely stable properties.³⁰

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 AuNC functionalization resulted in a large shift of UV-Vis plasmon absorption from 802 to
33 860 nm, characteristic of the dielectric constant change due to peptide and PEG conjugation to
34 the particle surface (Figure 2d). This was also confirmed by changes in electrokinetic and size-
35 distribution features of nanoparticles determined by DLS and zeta-potential analyses. The
36 hydrodynamic size of the nanoconjugates slightly increased, while their zeta-potential values
37 became less negative compared to non-functionalized nanocages (see Table 1). The peptide
38 amount per particle was evaluated by UV-vis spectroscopy on washing supernatant by
39 subtracting a reference blank obtained as a mixture of PEG and dimethylsulfoxide at the same
40 amounts and conditions of the reaction. On average, we found around 2000 peptide molecules
41 per particle (Table 1). The long-term colloidal stability was monitored by DLS and zeta-potential
42 measurements for several months after peptide conjugation, (Figure S2). The nanoparticles were
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

highly stable in mQ water as monitored by UV-vis spectroscopy and after incubation in different buffer solutions, including acetate buffer (pH 4.5), 20 mM HEPES (pH 7.8), 2.5 mM NaCl (pH 2 and pH10) and fetal bovine serum (FBS) (Figure S3, a-c). Surprisingly, all nanoconjugates were found to be stable both in 100% FBS and in acidic sodium chloride solution (pH 2), as confirmed by the very slight changes in the position and intensity of the plasmonic band. Halas *et al.* have investigated the stability of Ag-Au hollow nanospheres across a range of different pH and in human serum at physiological pH.²⁴ Disappointingly, the authors noticed that the structural integrity of the hollow architecture was compromised both in serum and in strongly acidic pH causing the *in vivo* degradation of AuNCs.




Figure 2. a) TEM micrographs of as-prepared silver nanocubes - medium size 34.7 ± 2.5 nm (scale bar 50 nm); b) TEM micrographs of as-prepared Au-PVP NCs (scale bar 500 nm); c) TEM micrographs of as-prepared Au-PVP NCs – medium size 40.8 ± 1.8 nm (scale bar 50 nm); d) UV-vis spectra of AuNCs before and after functionalization with peptides.

This effect was attributed to the presence of Ag on the inner surface of the nanoparticles leading to oxidation and consequent alteration of the integrity of the particles. In contrast, the structural integrity of our AuNCs was maintained in FBS, and no silver leakage was observed by TEM analysis. This improved stability is attributable to the presence of Au layers both inside and outside the cage walls, protecting them from oxidation and making them stable under the aggressive biological conditions (Figure S3).²⁵ Moreover, a careful design of the ligand shell to protect the nanoparticles from aggregation, using both CALNN pentapeptide and PEG at right proportion, has contributed to the particle stability even at harsh conditions.³⁰

Table 1. Hydrodynamic size (DLS), zeta-potential and ligand shell composition of nanoparticles:

1 - Au-PVP, 2 - Au-CALNN-INP, 3 - Au-CALNN-YIN, 4 - Au-CALNN-Ahx-INP.

N°	Hydrodynamic size, nm	Zeta-potential, mV	peptide/NP
1	44.25 ± 13.45, PDI 0.154	-32.7 ± 4.20	-
2	45.56 ± 12.87, PDI 0.189	-5.66 ± 7.47	2.04 × 10 ³
3	51.92 ± 14.27, PDI 0.160	-4.80 ± 5.62	1.67 × 10 ³
4	50.04 ± 17.51, PDI 0.225	-4.11 ± 3.98	2.50 × 10 ³


NPYR targeting. A nanoconjugate drug or diagnostic agent with potential impact in the clinics should have a distinct capacity to target the disease *in-situ*. Either passive or active targeting have been explored in details so far. Besides the “enhanced permeability and retention” (EPR) effect, passive targeting largely exploits also intrinsic physico-chemical characteristics of nanoparticles, including charge, size, shape and material composition.³¹ For example, cationic nanoparticles electrostatically bind to negatively charged phospholipid head-groups exposed on the cell surface, while lipid nanoparticles can fuse with the cell membrane and enter the cell without involving the interaction with any specific receptor.^{32,33} On the other hand, active targeting requires the interaction between a conjugated targeting ligand and a molecular receptor,

1
2
3 preferentially a protein or a carbohydrate molecule or cluster, overexpressed on the outer surface
4 of the cell.³⁴ Competitive binding or using scrambled peptides (or nonspecific antibodies) are
5 two major approaches to characterize the active targeting efficiency of functionalized
6 nanoparticles. In the first approach, targeted particles are incubated with receptor-positive cells
7 in the presence of large (usually 10 to 100-fold) excess of free ligand, so that nanoparticle
8 binding is initially hampered by the receptor saturation.³⁵ In the second approach, peptides with
9 randomly mixed amino acid sequences are used to show decreased binding efficiency of
10 nanoparticles.³⁶ Both approaches have their advantages and disadvantages and thus multiple
11 strategies should be used to assess specific receptor binding. Another approach, commonly used
12 in molecular biology to study receptor-ligand interactions, includes the assessment of signal
13 transduction activation upon receptor binding. Here we propose to use this approach to prove the
14 specific molecular binding of nanoparticles to the cellular receptors, taking advantage of the
15 intracellular biochemical events triggered by the receptor binding process. Once cells recognize
16 targeting molecules on the nanoparticle surface, they respond to extracellular stimuli by
17 engaging specific intracellular programs, including the signaling cascade that leads to the
18 activation of regulatory sentinel genes, such as the mitogen-activated protein kinases (MAPKs).
19 This chain of reactions, called intracellular signal transduction, allows signal to be transmitted
20 from the cell surface to a variety of intracellular targets. We reasoned that the detection of the
21 activation/deactivation of different downstream signals induced by the nanoparticle binding to
22 the receptor could be a corroborating proof of the involvement of ligand-receptor active
23 recognition compared to conventional assays. In other words, when peptide-conjugated
24 nanoparticle binds to NPY receptor on PC3 cell, a signaling cascade activation takes place. In
25 particular, we focused on the phosphorylation of the extracellular signal-regulated kinase (ERK),
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 which is a pivotal step of the cytosolic signaling pathway associated with NPYR activation. ERK
4 belongs to the MAPK pathway, and its activation plays a key role in the signaling process
5 leading to cell proliferation induced by growth factors that act through either protein-tyrosine
6 kinase or G protein-coupled receptors.^{37,38} Activation of ERK is mediated by the Raf/Ras/MEK
7 pathway, where MEK activates members of the ERK family by phosphorylation of both
8 threonine and tyrosine residues. Once activated, ERK phosphorylates a variety of targets,
9 including other protein kinases and transcription factors.³⁹ Lee et al. reported that heregulin-
10 functionalized nanorods binding to HER2 receptor could stimulate ERK phosphorylation in
11 MCF7 breast cancer cells.⁴⁰ The increase in ERK phosphorylation was associated to the
12 existence of “active zones,” i.e., dynamic regions in the cell periphery, exhibiting higher rates of
13 nanoparticle binding compared to the rest of the cell, suggesting, therefore, a localized receptor
14 activation.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 In our experiments, we first confirmed that the chemical modification of peptides required for
33 AuNC conjugation did not compromise their ability to bind to the receptors. For this purpose, we
34 analyzed ERK phosphorylation after incubation of PC3 cells with free peptides. All experimental
35 conditions (peptide concentration, incubation time) were set up basing on our previous
36 expertise.²¹ All three peptides at 10^{-7} M concentration induced a significant level of ERK
37 phosphorylation within 10 min (Figure 3). As we expected, the comparison between the shortest
38 peptide under investigation, i.e., CALNN-INP, and its Ahx-modified analogue showed that the
39 highest phosphorylation ratio (~%) was achieved with the short peptide associated with a good α -
40 helix conformation. As for CALNN-YIN peptide, its pERK/ERK ratio of reached ~260-270% at
41 10^{-7} M peptide concentration. After 20 min incubation, pERK/ERK ratio decreases in all three
42 cases, almost reaching control levels, which is indicative of short-term phosphorylation.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Next, in order to assess the downstream intracellular signaling upon nanoparticle binding, ERK phosphorylation was measured in PC3 cells targeted with peptide-conjugated AuNCs. Figure 3 shows that all Au-peptide NCs were indeed able to stimulate ERK activation, therefore confirming the occurrence of a specific interaction with NPYR. Generally, the response of ERK activation is both enhanced (~150%-250%) and prolonged (from 10 to 20 min) compared to the respective free peptides, depending on the peptide sequence. This effect was likely associated to the presence of the nanocage.



1
2
3 **Figure 3.** Time dependence of ERK phosphorylation in PC3 cells in response to specific NPYR
4 targeting by nanocages decorated with a) CALNN-INP, b) CALNN-Ahx-INP, and c) CALNN-
5 YIN peptides. Number of replicates, n = 3.
6
7
8
9

10
11 Indeed, multivalent interaction between peptides and receptors could take place due to higher
12 ligand density on the particle surface leading to higher binding avidity. In addition, the
13 distribution of peptide molecules on the nanoparticle surface was regular due to both CALNN
14 and PEG contribution, leading to a more appropriate presentation of the peptide binding motif to
15 the receptor interaction site.
16
17
18
19
20
21

22
23 Our findings are corroborated by previous evidence by Chan and co-workers that spherical
24 gold nanoparticles conjugated with anti-HER2 antibody could firmly anchor on SK-BR-3 cell
25 surface, resulting in prolonged receptor binding compared to the antibody alone.⁴⁰ The authors
26 showed that nanoparticle size between 40-50 nm is critical to be internalized via receptor-
27 mediated endocytosis, keeping a balance between multivalent cross-linking of membrane
28 receptors and the process of membrane wrapping involved in clathrin polymerization required
29 for the endosomal vesicle formation. We evaluated the influence of the peptide structure on the
30 interaction with NPYR and, consequently, on ERK stimulation. All peptides showed high levels
31 of phosphorylation compared to the control. Unexpectedly, the longer peptide CALNN-Ahx-
32 INP, once bound to nanoparticle, showed even higher phosphorylation levels compared to its
33 shorter analog, CALNN-INP, in contrast to the response of the peptide alone (Figure 3, a, b). Au-
34 CALNN-YIN NPs confirmed their efficiency showing extremely high pERK/ERK ratios at short
35 incubation time, and a prolonged effect up to 60 min after incubation (Figure 3c).
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52

53 **Assessment of AuNC uptake by confocal microscopy.** Thanks to their unique optical
54 absorption and scattering properties, gold nanoparticles, as small as 4 nm in size, can be detected
55
56
57
58
59
60

1
2
3 inside the cells by laser confocal scanning microscopy in scattering (reflective) mode, as reported
4
5 by Rotello et al.⁴¹ Also, larger anisotropic gold nanoparticles can be detected in living cells and
6
7 followed in their intracellular dynamics.⁴² In our study, we applied this technique to investigate
8
9 the internalization kinetics of NPY-conjugated AuNCs into PC3 cells. As shown in Figure 4, the
10
11 most part of peptide-conjugated nanoparticles were found either crossing the cellular membrane
12
13 or inside the cells after 1 h of incubation. Quite surprisingly, Au-PVP nanocages missing the
14
15 peptide ligand were hardly taken up by the cells (Figure S5), suggesting very high selectivity of
16
17 peptide-mediated nanoconjugate internalization. As observed from histograms in Figure 4d and
18
19 from the kinetic analysis (Figure S6), Au-CALNN-YIN NPs have the fastest internalization
20
21 kinetics with growth time 3 ± 1 h, and shows an overshooting effect at about 5 h of incubation
22
23 time with a subsequent relaxation time of about 24 ± 1 h. The kinetics of internalization of Au-
24
25 CALNN-INP NPs shows a single growth component (Figure S6) with relaxation time = 3 ± 1 h.
26
27 The growth kinetics of its longer analog is slower with growth time = 6 ± 1.3 h. Notably, after 24
28
29 h of incubation, the amount of Au nanocomposites internalized by the cells reached a basically
30
31 common value among the three different Au-peptide nanocages. For a better understanding, full-
32
33 size confocal microscopy images are reported in SI (Figure S4A-D).

34
35
36 These results are in line with the data from ERK-phosphorylation investigations, where the
37
38 highest pERK/ERK ratio was attributed to Au-CALNN-YIN NPs, in fact, showing the fastest
39
40 accumulation kinetics. The major cellular uptake, and, as a consequence, higher pERK level,
41
42 could be attributed to higher affinity of YIN peptide sequence not only to Y1 receptor ($ED_{50} = 9$
43
44 nM), but also to Y2 receptor ($IC_{50} = 8$ nM), while INP peptide sequence was found to have
45
46 affinity only to Y1 receptor subtype ($IC_{50} = 10$ nM versus $IC_{50} = 480$ nM for Y2 receptor).⁴³
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Confocal microscopy images ($162 \mu\text{m} \times 162 \mu\text{m}$) of PC3 cells incubated with peptide-functionalized AuNCs: a) Au-CALNN-INP NPs; b) Au-CALNN-Ahx-INP NPs; c) Au-CALNN-YIN NPs. Cellular membranes are stained with AlexaFluor488-conjugated Wheat germ agglutinin (green), while AuNCs are visualized in reflection mode (red); d) Cellular uptake quantification by confocal microscopy. Scattering signal per cell area is reported after measuring

1
2
3 at least 50 cells per sample. The nanoparticle uptake, evaluated by summing the scattering signal
4
5 from all the nanoparticles inside each cell normalized to the cell section area, was averaged over
6
7
8 at least 50 cells.
9

10
11 **Determination of nanoparticle uptake and trafficking by transmission electron**
12 **microscopy.** In order to get insight into the interaction between the nanoconjugates and the
13
14 cellular environment, the nanocage trafficking pathway inside the cells was studied by TEM.
15
16 PC3 cells were incubated with the particles for different periods of time (from 30 min to 48 h) at
17
18 37 °C, then washed, harvested and processed following a common preparation protocol. Figure 5
19
20 and Figure S7 show TEM images of cross-sectioned PC3 cells incubated with Au-CALNN-YIN
21
22 NCs and Au-CALNN-INP NCs, respectively. After 30 min of incubation, AuNCs were found
23
24 confined at the cellular membrane, suggesting the occurrence of ligand binding to the relevant
25
26 NPY receptor. According to the TEM analyses, we speculated that mainly two internalization
27
28 mechanisms were likely to take place, basically micropinocytosis and clathrin-mediated
29
30 endocytosis. In most cases, a well-preserved double membrane of the vesicles characteristic of
31
32 endocytosis pathway could be distinguished.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. Gallery of TEM images showing cellular trafficking of Au-CALNN-YIN NCs in PC3 cells. The nanocages were incubated with cells for 30 min, 3, 5, 24 and 48 h, processed and visualized by TEM microscopy. Scale bars: a,c) 200 nm; b,e,f) 1 μm; d,g) 500 nm; h) 2 μm. Small arrows indicate just internalized nanocages, while big arrows indicate clathrin formation.

24 h, carefully washed with buffer to remove all residual nanocages from the matrix and re-incubated in the fresh media for additional 5 and 24 h. Figure 6 and Figure S8 show the presence of nanoparticles inside the vesicles throughout the cell, both close to the nucleus and to the cell membrane. As observed, vesicles were trafficked back to the cellular membrane and subsequently excreted. Eventually, exocytosed vesicles released the nanoparticles outside the cells, which were next endocytosed again (5 h and 24 h). The competitive action of faster and predominant endocytosis with slower relaxing exocytosis might be at the origin of the higher intracellular concentration of Au-CALLN-YIN constructs observed at 5 h (see Fig. 4 and Fig. S12) compared to the equilibrium value reached at longer incubation times (24 h).




Figure 6. Gallery of TEM images showing PC3 cells incubated with Au-CALNN-YIN NCs: the cells were treated with nanocages for 24 h and washed with fresh medium (T = 0 h), then re-incubated for further 5 h (T = 5 h) or 24 h (T = 24 h). Scale bars: a) 2 μm ; b,c,e,f) 500 nm; d,g) 5 μm ; h,i) 1 μm .

1
2
3 **Photothermal ablation of prostate cancer cells.** Among different plasmonic nanoparticles,
4 the interest in using gold nanocages as a tool for photothermal ablation of cancer has been
5 dramatically rising thanks to their unique ability to absorb near-infrared (NIR) light in the
6 650–900 nm range, the so-called biologically transparent window.^{45,46} Thus, we moved to
7 investigate the efficiency of targeted AuNCs in inducing prostate cancer cell death via
8 photothermal treatment. First, we studied the thermal-responsiveness of AuNCs in solution in
9 order to define the maximum temperature rise at a given nanoparticle concentration (i.e., 0.4
10 nM). We exposed AuNCs in PBS to NIR laser irradiation at 800 nm with laser irradiance varying
11 from 1.6 to 12.7 W/cm² for 20 min. Changes in temperature were measured and imaged by a
12 thermographic camera over the whole duration of the experiments. As shown in Figure S9, the
13 temperature of AuNCs increased from ca. 6 °C at the lowest irradiance (1.6 W/cm²) to 35 °C at
14 the highest (12.7 W/cm²). In contrast, under the same conditions, the temperature of
15 nanoparticle-free PBS solution increased only by 2 °C.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 Next, to quantify the photothermal efficiency of nanoconjugates in cell cultures, we assessed
35 the cell viability upon treatment with AuNCs. MTS assay was performed on PC3 cells incubated
36 with nanoconjugates before and after laser irradiation. Cell viability was not compromised after
37 incubation with peptide-conjugated AuNCs at 0.4 nM concentration for as long as 72 h of
38 incubation (Figure S10). In contrast, upon irradiating the sample at an irradiance as low as 1.6
39 W/cm², cell viability drastically dropped even after the shortest irradiation time (30 sec) (Figure
40 S11). At longer irradiation times, cell viability reached a plateau with similar values for all of the
41 three nanoconjugates. Due to the experimental conditions, cell viability never reached zero
42 values (a minimum 25% was found). This residual viability is likely attributable to the average
43 fraction of cell pellet not irradiated in the Eppendorf tube due to the finite size of the laser spot
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 that should be confined in a small volume (1.6-1.8 mm linear size) in order to reach the desired
4
5 irradiance value. Not surprisingly, cell viability was mostly compromised in the case of Au-
6
7 CALNN-YIN NPs even after 30 s of irradiation. This result is in line with the cellular uptake
8
9 studies showing the maximum accumulation of Au-CALNN-YIN NCs already after 3 h
10
11 incubation, different from the other two nanoconjugates.
12
13
14




Figure 7. Fluorescence microscopy images of PC3 cells incubated with peptide-conjugated AuNCs: a) AuNCs upon NIR irradiation (800 nm, 12.7 W/cm²) for 10 min; b) AuNCs upon NIR irradiation (800 nm, 12.7 W/cm²) for 20 min. Viable cells are stained in green with calcein AM, dead cells are stained in red with PI. All images were collected in tile mode: the overall field of view is 3.1 · 3.1 mm.

In order to assess the tumorigenic cell ablation efficacy of peptide-conjugated AuNCs, we visualized the effect of NIR laser irradiation on a large field of view by means of confocal microscopy. All irradiation experiments were performed at room temperature. PC3 cells were cultured in a glass-bottomed Petri dish and incubated for 3 h with nanoconjugates at a final

1
2
3 concentration of 0.4 nM. Cells were irradiated for 10 and 20 min at 10 W/cm² irradiance, then
4
5 stained with calcein AM and propidium iodide (PI) following a standard staining protocol and
6
7 immediately observed by fluorescence microscopy. This assay is based on the conversion of the
8
9 cell permeant non-fluorescent calcein AM dye to the fluorescent analog by intracellular esterase
10
11 activity in live cells,⁴⁷ which allowed us to visualize the alteration of live/dead cells ratio caused
12
13 by the photothermal effect of AuNCs. On the other hand, PI is membrane impermeable and does
14
15 not enter viable cells with intact membranes, while once the cell undergoes membrane damage,
16
17 PI intercalates into nucleic acids giving rise to dramatic fluorescence increase. As shown in
18
19 Figure 7a, following 10 min of irradiation, the cells maintained their viability, even when treated
20
21 with peptide-conjugated nanocages. When irradiation time was increased to 20 min, the cells
22
23 underwent death principally by necrosis: a clear demarcation line between dead (red) and live
24
25 (green) cell regions could be observed in the presence of AuNCs. By contrast, the irradiation of
26
27 the untreated cells with the same laser power did not lead to cell death, confirming the safety of
28
29 our experimental conditions. Moreover, the irradiation of plated cells at irradiance at 2 W/cm² or
30
31 below did not produce any significant reduction of the calcein staining. This disagreement with
32
33 the data from confocal microscopy raised a question: were the calcein-positive cells really alive
34
35 or did they rather underwent cell death pathway, which could not be detected by this kind of
36
37 staining? In order to resolve this question, more detailed studies on apoptosis pathway will be
38
39 necessary. Temperature increase was recorded by a thermocamera while irradiating cells
40
41 incubated either with Au-PVP NCs or with Au-peptide NCs. Thermograms shown in Figure 8
42
43 suggested that, at 12.7 W/cm² irradiance and 5 min irradiation time, control cells that were not
44
45 incubated with AuNCs exhibited a negligible temperature change around 1 °C.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 8. Upper panel: Time-dependent temperature-rise images of PC3 cells incubated with peptide-conjugated AuNCs, Au-PVP NCs and control cells. The pictures were obtained by thermocamera during laser exposure and show the Petri dish (35 mm diameter) with the central irradiated area. Lower panel: Time-dependent temperature-rise curves of PC3 cells incubated with peptide-conjugated AuNCs, Au-PVP NCs and control cells. Time interval: 5 min. Laser irradiance 12.7 W/cm^2 , 800 nm.

1
2
3 When incubated with Au-PVP NCs, the temperature rise was slightly higher, but did not even
4 reach 25 °C. This is in agreement with the low cellular uptake of these particles in PC3 cells. In
5
6
7
8 contrast, when cells were incubated with Au-CALNN-INP NPs, the thermocamera revealed a
9
10 significant heating with temperature approaching 35 °C, while even higher values, i.e., close to
11
12 44-45 °C, were reached with Au-CALNN-YIN NPs. These results are in accordance with MTS
13
14 studies and fully correlate with cellular uptake assessment in PC3 cell cultures. Au-CALNN-YIN
15
16 showed the major uptake and the lowest cell viability compared to the other samples. This
17
18 temperature enhancement can be considered as an underestimated value of the actual temperature
19
20 reached inside the cell, principally due to heat dissipation by the cell medium. However, our
21
22 measurement could provide a good estimate of the heat pumped in the cell by the NIR absorption
23
24 of the internalized nanocages, that leads to an intracellular temperature enhancement in the 10-20
25
26 degrees range.
27
28
29
30

31
32 Morphological changes of cell cytoskeleton upon laser treatment could give an idea of the
33
34 occurred cellular damage. To perform these studies we used scanning electron microscopy
35
36 (SEM). The cells, exposed to 10 min of laser irradiation at above conditions, were processed and
37
38 analyzed by SEM. Temperature rise during irradiation experiment was monitored with
39
40 thermocamera (Figure 8). The maximum temperature reached during irradiation was around 43
41
42 °C for Au-CALNN-YIN NCs, which correlates with the results of maximum cellular uptake.
43
44 While the temperature of the cells, incubated with Au-PVP NCs did not show significant
45
46 temperature rise, very similar to the control cells. Figure 9 indicates visible cellular damage after
47
48 nanoparticle-induced hyperthermia. Untreated PC3 cells showed the presence of numerous
49
50 characteristic microvilli on the cell surface both before and after exposure to NIR laser
51
52 irradiation. In contrast, cells treated with Au-PVP NCs and exposed to NIR radiation showed
53
54
55
56
57
58
59
60

1
2
3 some morphological changes, such as membrane blebbing and partial reduction in microvilli
4 exposure (Figure 9, c). Blebbing was indicative of occurred apoptosis after laser treatment when
5
6 the cell becomes spherical, shaping itself as imposed by the cytoskeleton. As a next step, cell
7
8 was digested and blebs or vesicles formed on its surface. On the other hand, cells treated with
9
10 Au-PVP NCs but not exposed to the laser did not exhibit evidence of damage or apoptosis
11
12 (Figure 9, d). PC3 cells showed complete loss of microvilli with simultaneous shrinkage in size
13
14 compared to non-irradiated cells after treatment with Au-CALNN-INP NPs and exposed to NIR
15
16 irradiation (Figure 9, e, f). Finally, cells treated with Au-CALNN-YIN NPs revealed a
17
18 smoothing of cell surface showing complete loss of surface microvilli and a different
19
20 morphological aspect compared to both Au-PVP NCs and Au-CALNN-INP NPs, suggesting a
21
22 more relevant effect of hyperthermia on the cytoskeleton organization. The presence of
23
24 microvilli on the surface of the malignant cells plays a role in cell migration, attachment and
25
26 invasion, while reduction in microvilli may potentially inhibit cancer cell invasion and, therefore,
27
28 prevent the disease development and diffusion.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 9. SEM images showing PC3 cell morphology changes pre- and post-hyperthermia treatment with AuNCs: a) untreated PC3 cells, b) PC3 cells irradiated with laser, c) PC3 cells incubated with Au-PVP NCs and irradiated with laser, d) PC3 cells incubated with Au-PVP NCs

1
2
3 without laser irradiation, e) PC3 cells incubated with Au-CALNN-INP NCs and irradiated with
4 laser, f) PC3 cells incubated with Au-CALNN-INP NCs without laser irradiation, g) PC3 cells
5 incubated with Au-CALNN-YIN NCs and irradiated with laser, and h) PC3 cells incubated with
6 Au-CALNN-YIN NCs without laser irradiation. Scale bars: a,d) 10 μm ; b,c,e,f) 3 μm ; g,h) 1 μm .
7
8
9
10
11

12 CONCLUSIONS

13
14 In summary, the design, synthesis and characterization of monodisperse cubic-shaped gold
15 nanocages functionalized with three different NPY analogs are reported in this study. The
16 peptides were conjugated via a CALNN linker sequence and intercalated by short PEG
17 molecules, allowing for an optimized self-assembly on the nanoparticle surface. The resulting
18 Au-peptide NCs proved to be unexpectedly long-term stable in biological environment, as no
19 cage degradation occurred even in 100% fetal bovine serum and in a broad range of pH (i.e.,
20 between 2 and 10). AuNCs were used to study the binding and internalization in a PC3 prostate
21 cancer cell line, showing highly selective interaction with NPYR and efficient uptake promoted
22 by clathrin-mediated endocytosis. TEM images showed a dynamic exchange of AuNCs between
23 the cytosolic environment and the external cellular matrix, suggesting an active trafficking
24 process of endocytosis/exocytosis/re-endocytosis across the cell membrane. Once loaded with
25 AuNCs, cancer cells were irradiated with NIR laser at ca. 800 nm wavelength showing a heating
26 enhancement dependent both on the irradiation intensity and nanoparticle uptake. Cells treated
27 with Au-peptide NCs were irradiated at 10 W/cm^2 showing extensive necrosis after 20 min.
28 However, further studies will be necessary to elucidate the possible involvement of apoptosis
29 pathways in the mechanism of cell death. Interestingly, we observed significant morphological
30 changes in the cell cytoskeleton caused by irradiation in PC3 cells bearing AuNCs, consistent
31 with cellular damage. In particular, the appearance of membrane blebbing combined with loss of
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 characteristic microvilli could be associated to possible apoptosis and is expected to inhibit both
4 proliferation and migration/invasion of cancer cells. The next steps of this research will be to go
5 deeper into the elucidation of death mechanisms of cells loaded with NPY-AuNCs promoted by
6 irradiation, and to investigate the intracellular pathways and protein expression activated or
7 inhibited as a result of photothermal treatment. On the horizon of this study, we envisage
8 numerous possible developments aimed at improving the diagnosis and treatment of different
9 kinds of tumors well beyond prostate cancer, considering that neuropeptide receptor is found
10 overexpressed in several malignancies, including glioblastoma, lymphomas, ovarian and breast
11 carcinomas, neuroblastoma, small cell lung cancer, gastric and colorectal carcinomas.^{48,49}
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 ASSOCIATED CONTENT

29
30
31 **Supporting Information.** Supporting Information is available free of charge on the ACS
32 Publications website. Peptide sequences, chemical structure and purity, peptide synthesis,
33 AuNCs preparation and functionalization, experimental methods, and supporting figures S1-S11
34 (all included in one pdf file).
35
36
37
38
39
40

41 AUTHOR INFORMATION

42 **Corresponding Author**

43
44
45
46
47 * Davide Prospero: davide.prosperi@unimib.it
48
49

50 **Author Contributions**

51
52
53 The manuscript was written through contributions of all authors. All authors have given approval
54 to the final version of the manuscript.
55
56
57
58
59
60

1
2
3 **Notes**
4

5
6 The authors declare no competing financial interest.
7

8
9 **ACKNOWLEDGMENT**
10

11 S.A. acknowledges European Soft Matter Infrastructure (ESMI) program, Prof. Luis Liz-Marzà
12 and Ana Sanchez-Iglesias at biomaGUNE, San Sebastián, Spain. We especially thank Raffaele
13 Allevi (University of Milano) for help with electron microscopy and Stefania Brambilla for the
14 execution of mass spectrometry analyses. This project was supported by the Fondazione
15 Regionale per la Ricerca Biomedica of Regione Lombardia (FRRB to D.P. and M.C.) and by
16 Academic Funding Unimib 2014 to M.C and L.S.
17
18
19
20
21
22
23
24

25
26 **REFERENCES**
27

28
29 (1) Weiner, G. J. (2015) Building Better Monoclonal Antibody-Based Therapeutics. *Nat. Rev.*
30 *Cancer*, 15, 361–370.
31

32
33
34 (2) Wurz, G. T.; Kao, C. J.; De Gregorio, M. W. (2016) Novel Cancer Antigens for
35 Personalized Immunotherapies: Latest Evidence and Clinical Potential. *Ther. Adv. Med. Oncol.*
36 8, 4–31.
37
38
39

40
41
42 (3) Chames, P.; Van Regenmortel, M.; Weiss, E.; Baty, D. (2009) Therapeutic Antibodies:
43 Successes, Limitations and Hopes for the Future. *Br. J. Pharmacol.*, 157, 220–233.
44
45
46

47
48 (4) Shefet-Carasso, L.; Benhar, I. (2015) Antibody-Targeted Drugs and Drug Resistance –
49 Challenges and Solutions. *Drug Resist. Updates*, 18, 36–46.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (5) Morgat, C.; Mishra, A. K.; Varshney, R.; Allard, M.; Fernandez, P.; Hindié, E. (2014)
4 Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with
5 Bombesin, Neurotensin, and Neuropeptide-Y Receptors. *J. Nucl. Med.*, 55, 1650–1657.
6
7

8
9
10
11 (6) Reubi, J.C. (2003) Peptide Receptors as Molecular Targets for Cancer Diagnosis and
12 Therapy. *Endocrine Rev.*, 24, 389–427.
13
14

15
16
17 (7) Jensen, R. T. (2000) Carcinoid and Pancreatic Endocrine Tumors: Recent Advances in
18 Molecular Pathogenesis, Localization, and Treatment. *Curr. Opin. Oncol.*, 12, 368–377.
19
20

21
22 (8) Fani, M.; Maecke, H. R.; Okarvi, S. M. (2012) Radiolabeled Peptides: Valuable Tools for
23 the Detection and Treatment of Cancer. *Theranostics*, 2, 481–501.
24
25

26
27
28 (9) Huang, H.-C.; Barua, S.; Sharmad, G.; Dey, S. K.; Rege, K. (2011) Inorganic
29 Nanoparticles for Cancer Imaging and Therapy. *J. Controlled Rel.*, 155, 344–357.
30
31

32
33 (10) Xia, Y.; Li, W.; Cobley, C. M.; Chen, J.; Xia, X.; Zhang, Q.; Yang, M.; Cho, E. C.;
34 Brown, P. K. (2011) Gold Nanocages: from Synthesis to Theranostic Applications. *Acc. Chem.*
35 *Res.*, 44, 914–924.
36
37

38
39
40
41 (11) Eichelbaum, M.; Schmidt, B.E.; Ibrahim, H.; Rademann, K. (2007) Three-Photon-Induced
42 Luminescence of Gold Nanoparticles Embedded in and Located on the Surface of Glassy
43 Nanolayers *Nanotechnology*, 18, 355702.
44
45
46

47
48
49 (12) Meir, R.; Motiei, M.; Popovtzer, R. (2014) Gold Nanoparticles for In Vivo Cell Tracking.
50 *Nanomedicine*, 9, 2059–2069.
51
52
53
54
55
56
57
58
59
60

1
2
3 (13) Zhang, Q.; Iwakuma, N.; Sharma, P.; Moudgil, B.M.; Wu, C.; McNeill, J.; Jiang, H.;
4 Grobmyer, S.R. (2009) Gold Nanoparticles as a Contrast Agent for In Vivo Tumor Imaging with
5 Photoacoustic Tomography. *Nanotechnology*, 20, 395102.
6
7

8
9
10
11 (14) Shi, P.; Liu, Z.; Dong, K.; Ju, E.; Ren, J.; Du, Y.; Li, Z.; Qu, X. (2014) A Smart “Sense-
12 Act-Treat” System: Combining a Ratiometric pH Sensor with a Near Infrared Therapeutic Gold
13 Nanocage. *Adv Mater.*, 26, 6635-6641.
14
15

16
17
18
19 (15) Shi, P.; Li, M.; Ren, J.; Qu, X. (2013) Gold Nanocage-Based Dual Responsive “Caged
20 Metal Chelator” Release System: Noninvasive Remote Control with Near Infrared for Potential
21 Treatment of Alzheimer's Disease. *Advanced Functional Materials*, 23, 5412-5419.
22
23

24
25
26
27 (16) Moran, C. H.; Wainerdi, S. M.; Cherukuri, T. K.; Kittrell, C.; Wiley, B. J.; Nicholas, N. W.;
28 Curley, S. A.; Kanzius, J. S.; Cherukuri, P. (2009) Size-Dependent Joule Heating of Gold
29 Nanoparticles Using Capacitively Coupled Radiofrequency Fields. *Nano Res.*, 2, 400–405.
30
31

32
33
34
35 (17) Cardinal, J.; Klune, J. R.; Chory, E.; Jeyabalan, G.; Kanzius, J. S.; Nalesnik, M.; Geller,
36 D. A. (2008) Noninvasive Radiofrequency Ablation of Cancer Targeted by Gold Nanoparticles.
37 *Surgery*, 144, 125–132.
38
39

40
41
42
43 (18) Chen, F.; Cai, W. (2015) Nanomedicine for Targeted Photothermal Cancer Therapy:
44 Where Are We Now? *Nanomedicine*, 10, 1–3.
45
46

47
48
49 (19) Hwang, S.; Nam, J.; Jung, S.; Song, J.; Doh, H.; Kim, S. (2014) Gold Nanoparticle-
50 Mediated Photothermal Therapy: Current Status and Future Perspective. *Nanomedicine*, 9,
51 2003–2022.
52
53
54
55
56
57
58
59
60

1
2
3 (20) Rozengurt, E. (2002) Neuropeptides as Growth Factors for Normal and Cancerous Cells.
4 Trends Endocrinol. Metab., 13, 128–134.
5
6

7
8
9 (21) Ruscica, M.; Dozio, E.; Boghossian, S.; Bovo, G.; Martos Riaño, V.; Motta, M.; Magni, P.
10 (2006) Activation of the Y1 Receptor by Neuropeptide Y Regulates the Growth of Prostate
11 Cancer Cells. Endocrinology, 147, 1466–1473.
12
13
14

15
16
17 (22) Cabrele C., Beck-Sickinger A. G. (2000) Molecular Characterization of the Ligand–
18 Receptor Interaction of the Neuropeptide Y Family. J. Peptide Sci., 6, 97–122.
19
20
21

22
23 (23) Lévy, R.; Thanh, N. T. K.; Doty, C. R.; Hussain, I.; Nichols, R. J.; Schiffrin, D. J.; Brust,
24 M.; Fernig, D. G. (2004) Rational and Combinatorial Design of Peptide Capping Ligands for
25 Gold Nanoparticles. J. Am. Chem. Soc., 126, 10076–10084.
26
27
28

29
30 (24) Allen, J.; Novotný, J.; Martin, J.; Heinrich, G. (1987) Molecular Structure of Mammalian
31 Neuropeptide Y: Analysis by Molecular Cloning and Computer-Aided Comparison with Crystal
32 Structure of Avian Homologue. Proc. Natl. Acad. Sci. USA, 84, 2532–2536.
33
34
35
36

37
38 (25) Leban J. J.; Heyer D.; Landavazo A.; Matthews J.; Aulabaugh A.; Daniels A. J. (1995)
39 Novel Modified Carboxy Terminal Fragments of Neuropeptide Y with High Affinity for Y2-
40 Type Receptors and Potent Functional Antagonism at a Y1-Type Receptor. J. Med. Chem., 38,
41 1150–1157.
42
43
44
45
46

47
48 (26) Whitmore, L.; Wallace, B. A. (2008) Protein Secondary Structure Analyses from Circular
49 Dichroism Spectroscopy: Methods and Reference Databases. Biopolymers, 89, 392–400.
50
51
52
53
54
55
56
57
58
59
60

1
2
3 (27) Andrade, M. A.; Chacón, P.; Merelo, J. J.; Morán, F. (1993) Evaluation of Secondary
4 Structure of Proteins from UV Circular Dichroism Spectra Using an Unsupervised Learning
5 Neural Network. *Prot. Engineering*, 6, 383–390.
6
7

8
9
10
11 (28) Zhang, Q.; Li, W.; Wen, L. P.; Chen, J.; Xia, Y. (2010) Facile Synthesis of Ag Nanocubes
12 of 30 to 70 nm in Edge Length with CF_3COOAg as a Precursor. *Chem. Eur. J.*, 16, 10234–
13 10239.
14
15

16
17
18
19 (29) Khlebtsov, B. et al. (2011) Nanocomposites Containing Silica-Coated Gold–Silver
20 Nanocages and Yb–2,4-Dimethoxyhematoporphyrin: Multifunctional Capability of IR-
21 Luminescence Detection, Photosensitization, and Photothermolysis. *ACS Nano*, 5, 7077–7089.
22
23

24
25
26
27 (30) Lévy, R. (2006) Peptide-Capped Gold Nanoparticles: Towards Artificial Proteins.
28 *ChemBioChem*, 7, 1141–1145.
29
30

31
32
33 (31) Blanco, E.; Shen, H.; Ferrari, M. (2015) Principles of Nanoparticle Design for
34 Overcoming Biological Barriers to Drug Delivery. *Nat. Biotechnol.*, 33, 941–951.
35
36

37
38 (32) Heikkilä, E.; Martinez-Seara, H.; Gurtovenko, A. A.; Javanainen, M.; Hakkinen, H.;
39 Vattulainen, I.; Akola, J. (2014) Cationic Au Nanoparticle Binding with Plasma Membrane-like
40 Lipid Bilayers: Potential Mechanism for Spontaneous Permeation to Cells Revealed by
41 Atomistic Simulations. *J. Phys. Chem. C*, 118, 11131–11141.
42
43
44

45
46
47
48 (33) Lin, J.; Alexander-Katz, A. (2013) Cell Membranes Open “Doors” for Cationic
49 Nanoparticles/Biomolecules: Insights into Uptake Kinetics. *ACS Nano*, 7, 10799–10808.
50
51

52
53
54 (34) Fiandra, L.; Mazzucchelli, S.; De Palma, C.; Colombo, M.; Allevi, R.; Sommaruga, S.;
55 Clementi, E.; Bellini, M.; Prospero, D.; Corsi, F. (2013) Assessing the In Vivo Targeting
56
57
58
59
60

1
2
3 Efficiency of Multifunctional Nanoconstructs Bearing Antibody-Derived Ligands. *ACS Nano*, 7,
4
5 6092–6102.
6
7

8
9 (35) Avvakumova, S.; Fezzardi, P.; Pandolfi, L.; Colombo, M.; Sansone, F.; Casnati, A.;
10
11 Prosperi, D. (2014) Gold Nanoparticles Decorated by Clustered Multivalent Cone-
12
13 Glycocalixarenes Actively Improve the Targeting Efficiency Toward Cancer Cells. *Chem.*
14
15 *Commun.*, 50, 11029–11032.
16
17

18
19 (36) Avvakumova, S.; Galbiati, E.; Pandolfi, L.; Mazzucchelli, S.; Cassani, M.; Gori, A.;
20
21 Longhi, R.; Prosperi, D. (2014) Development of U11-Functionalized Gold Nanoparticles for
22
23 Selective Targeting of Urokinase Plasminogen Activator Receptor-Positive Breast Cancer Cells.
24
25 *Bioconjugate Chem.*, 25, 1381–1386.
26
27

28
29 (37) Zhang, W.; Liu, H. T. (2002) MAPK Signal Pathways in the Regulation of Cell
30
31 Proliferation in Mammalian Cells. *Cell Res.*, 12, 9–18; b) McCubrey; J. A.; Steelman, L. S.;
32
33 Chappell, W. H., Abrams, S. L.
34
35

36
37 (38) Wong, E. W. T. et al. (2007) Roles of the Raf/MEK/ERK Pathway in Cell Growth,
38
39 Malignant Transformation and Drug Resistance. *Biochim. Biophys. Acta*, 1773, 1263–1284.
40
41

42
43 (39) Chang, F.; Steelman, L. S.; Lee, J. T.; Shelton, J. G.; Navolanic, P. M.; Blalock, W. L.;
44
45 Franklin, R. A.; McCubrey, J. A. (2003) Signal Transduction Mediated by the
46
47 Ras/Raf/MEK/ERK Pathway from Cytokine Receptors to Transcription Factors: Potential
48
49 Targeting for Therapeutic Intervention. *Leukemia*, 17, 1263–1293.
50
51

52
53 (40) Kilinc, D.; Lesniak, A.; Rashdan, S. A.; Gandhi, D.; Blasiak, A.; Fannin, P. C.; von
54
55 Kriegsheim, A.; Kolch, W.; Lee, G. U. (2015) Mechanochemical Stimulation of MCF7 Cells
56
57
58
59
60

1
2
3 with Rod-Shaped Fe–Au Janus Particles Induces Cell Death Through Paradoxical
4
5 Hyperactivation of ERK. *Adv. Healthcare. Mat.*, 4, 395–404.
6
7

8
9 (41) Jiang, W.; Kim, B. Y. S.; Rutka, J. T.; Chan, W. C. W. (2008) Nanoparticle-Mediated
10 Cellular Response Is Size-Dependent. *Nat. Nanotech.*, 3, 145–150.
11
12

13
14 (42) Kim, C. S.; Li, X.; Jiang, Y.; Yan, B.; Tonga, G. Y.; Ray, M.; Solfiell, D. J.; Rotello, V.
15 M. (2015) Cellular Imaging of Endosome Entrapped Small Gold Nanoparticles. *Methods*, 2,
16 306–315.
17
18
19

20
21 (43) Bouzin, M.; Sironi, L.; Chirico, G.; D’Alfonso, L.; Inverso, D.; Pallavicini, P. Collini, M.
22 (2015) An Intermittent Model for Intracellular Motions of Gold Nanostars by k-Space Scattering
23 Image Correlation. *Biophys. J.*, 109, 2246–2258.
24
25
26
27

28
29 (44) Grundemar, L., Ed.; Bloom, S. R. (1997) Ed. *Neuropeptide Y and Drug Development*;
30 Academic Press.
31
32
33

34
35 (45) Bartczak, D.; Nitti, S.; Millar, T. M.; Kanaras, A. G. (2012) Exocytosis of Peptide
36 Functionalized Gold Nanoparticles in Endothelial Cells. *Nanoscale*, 4, 4470–4472.
37
38
39

40
41 (46) Pansare, V.; Hejazi, S.; Faenza, W.; Prud’homme, R. K. (2012) Review of Long-
42 Wavelength Optical and NIR Imaging Materials: Contrast Agents, Fluorophores, and
43 Multifunctional Nano Carriers. *Chem. Mater.*, 24, 812–827.
44
45
46
47

48
49 (47) Wang, Z.; Chen, Z.; Liu, Z.; Shi, P.; Dong, K.; Ju, E.; Ren, J.; Qu, X. (2014) A Multi-
50 Stimuli Responsive Gold Nanocage-Hyaluronic Platform for Targeted Photothermal and
51 Chemotherapy. *Biomaterials*, 35, 9678–9688.
52
53
54
55
56
57
58
59
60

1
2
3 (48) Piao J.-G.; Liu, D.; Hu, K.; Wang, L.; Gao, F.; Xiong, Y.; Yang, L. (2016) Cooperative
4 Nanoparticle System for Photothermal Tumor Treatment without Skin Damage. ACS Appl.
5 Mater. Interfaces, 8, 2847–2856.
6
7
8
9

10
11 (49) Li, J.; Tian, Y.; Wu, A. (2015) Neuropeptide Y Receptors: A Promising Target for Cancer
12 Imaging and Therapy. Regener. Biomater. 2, 215–219.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Schematic representation of NPYR targeting on prostate cancer cells by peptide-functionalized gold nanocages and subsequent hyperthermia by NIR irradiation. Three kinds of AuNCs are considered, deriving from the surface functionalization with selected peptides, namely a) CALNN-INP, b) Au-CALNN-Ahx-INP, c) Au-CALNN-YIN, respectively. Peptide sequences are sketched in the figure. The available surface of AuNCs was saturated by short PEG molecules, HS-(CH₂)₁₁-EG₆-OH.

80x59mm (300 x 300 DPI)




Figure 2. a) TEM micrographs of as-prepared silver nanocubes - medium size 34.7 ± 2.5 nm (scale bar 50 nm); b) TEM micrographs of as-prepared Au-PVP NCs (scale bar 500 nm); c) TEM micrographs of as-prepared Au-PVP NCs - medium size 40.8 ± 1.8 nm (scale bar 50 nm); d) UV-vis spectra of AuNCs before and after functionalization with peptides.

140x99mm (300 x 300 DPI)




Figure 3. Time dependence of ERK phosphorylation in PC3 cells in response to specific NPYR targeting by nanocages decorated with a) CALNN-INP, b) CALNN-Ahx-INP, and c) CALNN-YIN peptides. Number of replicates, $n = 3$.

139x156mm (200 x 200 DPI)




Figure 4. Confocal microscopy images ($162 \mu\text{m} \times 162 \mu\text{m}$) of PC3 cells incubated with peptide-functionalized AuNCs: a) Au-CALNN-INP NPs; b) Au-CALNN-Ahx-INP NPs; c) Au-CALNN-YIN NPs. Cellular membranes are stained with AlexaFluor488-conjugated Wheat germ agglutinin (green), while AuNCs are visualized in reflection mode (red); d) Cellular uptake quantification by confocal microscopy. Scattering signal per cell area is reported after measuring at least 50 cells per sample. The nanoparticle uptake, evaluated by summing the scattering signal from all the nanoparticles inside each cell normalized to the cell section area, was averaged over at least 50 cells.

107x150mm (300 x 300 DPI)




Figure 5. Gallery of TEM images showing cellular trafficking of Au-CALNN-YIN NCs in PC3 cells. The nanocages were incubated with cells for 30 min, 3, 5, 24 and 48 h, processed and visualized by TEM microscopy. Scale bars: a,c) 200 nm; b,e,f) 1 μm; d,g) 500 nm; h) 2 μm Small arrows indicate just internalized nanocages, while big arrows indicate clathrin formation.

119x171mm (300 x 300 DPI)





Figure 6. Gallery of TEM images showing PC3 cells incubated with Au-CALNN-YIN NCs: the cells were treated with nanocages for 24 h and washed with fresh medium (T = 0 h), then re-incubated for further 5 h (T = 5 h) or 24 h (T = 24 h). Scale bars: a) 2 μm ; b,c,e,f) 500 nm; d,g) 5 μm ; h,i) 1 μm .

177x148mm (300 x 300 DPI)




25
26
27
28
29

Figure 7. Fluorescence microscopy images of PC3 cells incubated with peptide-conjugated AuNCs: a) AuNCs upon NIR irradiation (800 nm, 12.7 W/cm²) for 10 min; b) AuNCs upon NIR irradiation (800 nm, 12.7 W/cm²) for 20 min. Viable cells are stained in green with calcein AM, dead cells are stained in red with PI. All images were collected in tile mode: the overall field of view is 3.1 × 3.1 mm.

30
31
32

119x64mm (300 x 300 DPI)



46 Figure 8. Upper panel: Time-dependent temperature-rise images of PC3 cells incubated with peptide-
 47 conjugated AuNCs, Au-PVP NCs and control cells. The pictures were obtained by thermocamera during laser
 48 exposure and show the Petri dish (35 mm diameter) with the central irradiated area. Lower panel: Time-
 49 dependent temperature-rise curves of PC3 cells incubated with peptide-conjugated AuNCs, Au-PVP NCs and
 50 control cells. Time interval: 5 min. Laser irradiance 12.7 W/cm^2 , 800 nm.

51 160x188mm (200 x 200 DPI)




Figure 9. SEM images showing PC3 cell morphology changes pre- and post-hyperthermia treatment with AuNCs: a) untreated PC3 cells, b) PC3 cells irradiated with laser, c) PC3 cells incubated with Au-PVP NCs and irradiated with laser, d) PC3 cells incubated with Au-PVP NCs without laser irradiation, e) PC3 cells incubated with Au-CALNN-INP NCs and irradiated with laser, f) PC3 cells incubated with Au-CALNN-INP NCs without laser irradiation, g) PC3 cells incubated with Au-CALNN-YIN NCs and irradiated with laser, and h) PC3 cells incubated with Au-CALNN-YIN NCs without laser irradiation. Scale bars: a,d) 10 μm ; b,c,e,f) 3 μm ; g,h) 1 μm .

120x179mm (300 x 300 DPI)